Therapeutic mechanisms of psychedelics and entactogens

Heifets and Olson place psychedelics and entactogens in the context of a clinical resurgence: controlled, therapist-supported administrations of compounds such as MDMA and psilocybin have produced rapid and sometimes sustained benefits across conditions including PTSD, depression and substance use disorders. Despite promising clinical signals, the authors note an important translational gap. Preclinical animal work tends to emphasise receptor-level actions and measurable neuroplasticity, whereas human studies highlight subjective-state, contextual and psychotherapeutic factors (commonly summarised as "set, setting and integration") that are poorly modelled in laboratory species. This disconnect has limited mechanistic understanding and the ability to optimise these agents for safety, scalability and efficacy. The review aims to synthesise clinical and preclinical evidence to clarify candidate mechanisms by which psychedelics and entactogens could produce lasting therapeutic effects, to compare competing conceptual models, and to identify how circuit-level approaches might bridge human and rodent studies. The authors argue that, because these drugs are pharmacologically diverse, their rapid and sustained actions are best understood in terms of the neural circuits they engage rather than a single molecular target, and they propose directions for animal experimentation and translational research that reflect this perspective.

The extracted text presents a narrative, conceptual review rather than a systematic meta-analysis: it draws on clinical trials, human imaging and behavioural studies, and a range of preclinical approaches including electrophysiology, ex vivo and in vivo cellular work, optogenetics, chemogenetics and whole-brain activity mapping. The authors do not report a formal search strategy, databases searched, inclusion/exclusion criteria, or quantitative pooling of data in the provided text; therefore the methodological approach should be treated as selective synthesis of available literature rather than a reproducible systematic review. Organisation of the review is thematic. The authors contrast two mechanistic models (the "psychoplastogen" model in which drugs directly induce durable plasticity, and the "behavioral catalyst" model in which drugs facilitate psychotherapeutic learning), and then consider circuit-level evidence for classical psychedelics and for entactogens (MDMA). They integrate molecular and cellular findings (immediate early genes, spine dynamics, neurotransmitter release) with systems-level results (oscillations, functional connectivity) and behavioural paradigms (fear extinction, social reward, stress models). Finally, the review examines translational gaps—how preparation, dosing context and integration are modelled or neglected in animal studies—and concludes with proposed experimental priorities and clinical implications.

Several consistent themes and empirical observations emerge from the synthesized literature. First, classical psychedelics (e.g., LSD, psilocybin, DMT) and entactogens (principally MDMA) share two defining features across species: rapid-onset subjective effects and the capacity to induce persistent behavioural changes. These shared attributes motivate grouping them for mechanistic comparison despite diverse pharmacology. Evidence for drug-evoked structural and functional plasticity is substantial for classical psychedelics and for agents commonly labelled psychoplastogens. In cortex, psychedelics reliably induce immediate early genes such as c‑Fos and promote dendritic growth, increased dendritic spine density and changes in spine morphology. Ex vivo and in vivo studies, including two-photon imaging, show enhanced cortical spine formation after psilocybin, ketamine and 5-MeO-DMT; notably, a single psilocybin dose can elevate cortical spine density for up to one month. Psychedelics also provoke transient cortical glutamate bursts and alter oscillatory dynamics, with a characteristic decrease in low-frequency power and variable effects on gamma. Human imaging studies report reduced integrity of association-network connectivity following classical psychedelics, a pattern echoed in diverse psychedelic-like drugs. For MDMA and other entactogens, preclinical work has focused on circuits underlying social and fear-related behaviours, principally the nucleus accumbens (NAc) and basolateral amygdala. MDMA produces acute prosocial and affiliative behaviours across species and can produce lasting increases in social reward sensitivity. Several lines of evidence implicate serotonin release in the NAc as sufficient to evoke prosocial behaviour; oxytocinergic signalling interacts with these systems but does not appear strictly necessary for MDMA's acute effects. A candidate substrate for persistent MDMA effects is long-term depression (LTD) at excitatory synapses onto medium spiny neurons in the NAc, a form of plasticity that can be induced by MDMA and oxytocin and blocked by 5-HT1B antagonism. In fear-learning models, MDMA administered during extinction training can enhance extinction and reduce conditioned fear, and at least one study linked this effect to BDNF signalling in the amygdala. However, results across studies are not uniform: some reports find disruption of reconsolidation rather than enhanced extinction, and human paradigms yield mixed findings depending on the physiological readout used. The review contrasts two mechanistic frameworks. The psychoplastogen model posits that drug-induced neuroplasticity (for example, cortical spinogenesis) is sufficient to produce sustained therapeutic effects without psychotherapy. Supporting causal evidence comes from an experiment with ketamine in mice where photoablation of ketamine-induced dendritic spines abolished its sustained antidepressant-like effects, demonstrating a direct link between spinogenesis and behavioural rescue. Conversely, the behavioral catalyst model proposes that drugs transiently alter subjective state (for instance, reducing fear or increasing cognitive flexibility) and thereby enable psychotherapeutic processes—experience-dependent learning—that produce durable change. Animal data supporting catalyst-like mechanisms include context-dependent effects of MDMA on social behaviour and studies showing that drug timing relative to extinction training matters (MDMA before, but not after, extinction can enhance extinction memory). Translational gaps are emphasised. Most clinical trials of MDMA and psilocybin use a three-phase therapeutic structure—preparation, controlled drug administration and post‑drug integration—but animal studies rarely model these non-pharmacological elements. Expectancy effects, masking/blinding issues and ethical constraints complicate clinical mechanistic trials; the authors note an unpublished study where strong masking nullified differences between ketamine and control arms, underscoring the potential impact of expectancy. On integration, some clinical reports (for example, trials of ayahuasca and 5‑MeO‑DMT) show persistent antidepressant effects without structured integration, whereas ketamine studies often report short-lived effects in the absence of integration. Metaplasticity—the notion that a drug exposure changes the brain's capacity for future learning—appears in both human (psilocybin enhancing cognitive flexibility for weeks) and animal data (single-dose psychedelics or MDMA enabling social conditioned place preference in adult mice for weeks). Finally, the pharmacology is complex and not fully explanatory. 5‑HT2A receptor activation is implicated in many classical psychedelic effects, but antagonist studies have yielded incomplete blockade in some reports and other serotonin receptor subtypes and non-serotonergic receptors likely contribute. For MDMA, serotonin release via SERT is necessary for many effects, but dopamine release contributes to abuse liability; genetic or pharmacological manipulations (e.g., 5‑HT2B receptor deletion) can profoundly alter MDMA's neurochemical and behavioural profile.

The authors interpret the assembled evidence as consistent with a multi‑level, circuit-centred account of therapeutic action whereby rapid drug effects and more enduring changes emerge from modulation of distributed networks rather than from a single receptor action alone. Heifets and colleagues argue that psychoplastogen and behavioural-catalyst models are complementary: drug-induced biochemical plasticity may prime circuits for experience-dependent learning, while acute experiential effects may determine which circuits are engaged and how plasticity is consolidated. This hybrid perspective has practical consequences—if therapeutic versus adverse effects are separable at the circuit level, then circuit-targeted discovery and intervention strategies could yield safer, more scalable treatments. Relative to earlier work, the review highlights advances in systems neuroscience and circuit-dissection tools (optogenetics, chemogenetics, whole‑brain activity mapping) that enable more precise testing of mechanistic hypotheses. The authors emphasise the need to move beyond receptor binding screens toward assays that characterise how compounds alter circuit dynamics, plasticity and behaviour in context. Key limitations acknowledged in the text include the imprecision of animal models as surrogates for human psychiatric disease, sparse direct causal tests linking specific circuit/plasticity changes to human therapeutic outcomes, incomplete pharmacological dissection (antagonist studies produce ambiguous results), and a lack of systematic measurement of non‑pharmacological factors such as expectancy and integration in clinical trials. Ethical and practical constraints on manipulating set and setting in human subjects further complicate causal inference. For research and clinical practice, the authors recommend prioritising experiments that dissociate subjective-state-dependent from experience-independent plasticity, modelling preparation/setting/integration elements in animals where possible, and using circuit-level interventions to identify nodes mediating therapeutic versus adverse outcomes. They propose that such work could inform development of novel compounds or delivery models that retain rapid and sustained benefits while reducing side-effects and barriers to scale-up. Overall, the discussion urges an integrated translational programme combining modern circuit neuroscience with carefully designed human trials to resolve which processes are necessary and sufficient for durable therapeutic benefit.